ROI included sites that are commonly mutated in both primary and metastatic tumors (e.g., PIK3CA and TP53) as well as sites of putative metastatic driver mutations that we previously identified as specific to the metastatic tumor by WES (e.g., ESR1) [7]. The gene discussed is PIK3CA; the disease is metastatic neoplasm.